TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07051629: Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients

Sponsor: Suninflam Inc · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 88 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,160,896

Rescue Site Savings

+$765,136

Unlock Full NCT07051629 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07051629 Rescue Dossier →